Table 2 Summary of visual outcomes
Low-dose group Eyes: n = 36 | Intermediate-dose group Eyes: n = 31 | p | |
|---|---|---|---|
Initial BCVA | 1.2 ± 1.4(0.2 ~ 2.7) | 0.9 ± 1.8(0.1 ~ 2.7) | 0.663 |
Treatment-endpoint BCVA | 0.45 ± 1.18 | 0.5 ± 1.2 | 0.558 |
Final BCVA | 0.7 ± 1.15 | 0.7 ± 2.1 | 0.256 |
Final therapeutic efficacy | 0.815 | ||
Improved | 19/36 (52.8%) | 15/31 (48.4%) | |
Stable | 8/36 (22.2%) | 9/31 (29.0%) | |
Decreased | 9/36 (25.0%) | 7/31 (22.6%) |